Ikarian Capital, LLC Dia Medica Therapeutics Inc. Transaction History

Ikarian Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.86 - $2.62 $411,528 - $579,680	-221,252 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$2.29 - $3.88 $27,869 - $47,219	12,170 Added 5.82%	221,252 $553,000
Q4 2021 Feb 14, 2022	SELL	$3.43 - $4.65 $349,719 - $474,109	-101,959 Reduced 32.78%	209,082 $779,000
Q3 2021 Nov 15, 2021	SELL	$3.1 - $4.32 $322,272 - $449,102	-103,959 Reduced 25.05%	311,041 $1.25 Million
Q3 2020 Nov 16, 2020	BUY	$3.91 - $7.15 $1.62 Million - $2.97 Million	415,000 New	415,000 $1.76 Million

4.22M

8.2K

200

Ticker DMAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,443,100
Market Cap $128M
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.